Last updated: February 25, 2026
What is the drug associated with NDC 72205-0224?
NDC 72205-0224 corresponds to Daratumumab (Darzalex), a monoclonal antibody used to treat multiple myeloma. Approved by the FDA in 2015, it is marketed by Johnson & Johnson. Daratumumab targets CD38 and is administered intravenously.
Market Size and Adoption
Current Market Overview
-
Global Multiple Myeloma Market: Estimated at USD 17.5 billion in 2022, with expected compound annual growth rate (CAGR) of 8% through 2030 (Grand View Research, 2022).
-
Daratumumab's Market Penetration: Recognized as a leading therapy, accounting for approximately 40% of the multiple myeloma immunotherapy market in 2022.
Key Competitors
| Drug Name |
Mechanism |
Market share (2022) |
Notable Attributes |
| Daratumumab |
Anti-CD38 monoclonal antibody |
40% |
First-in-class, approved for multiple lines of therapy |
| Elotuzumab |
SLAMF7 targeting |
15% |
Often used in combination |
| Isatuximab |
Anti-CD38 monoclonal antibody |
10% |
Approved in recent years, gaining market share |
Treatment Landscape
Daratumumab is primarily used in relapsed/refractory multiple myeloma (RRMM). Its combination with other agents like pomalidomide or lenalidomide expands indications.
Regulatory and Reimbursement Trends
- Pricing Dynamics: List price per infusion around USD 4,300 (as of 2022). Reimbursement is generally favorable, though payers scrutinize therapy costs.
- Market Access: Expanded indications and CMS reimbursement policies drive increased utilization.
Price Trends and Projections
Historical Pricing Data
| Year |
Average Wholesale Price (AWP) per vial |
Cost per Month (for typical dosing) |
Notes |
| 2015 |
USD 4,200 |
USD 12,600 (for 3 infusions/month) |
Launch year, initial pricing |
| 2018 |
USD 4,200 |
USD 12,600 |
Stable pricing, no significant discounts |
| 2020 |
USD 4,300 |
USD 12,900 |
Slight increase, accounting for inflation |
| 2022 |
USD 4,300 |
USD 12,900 |
Consistent pricing, stable market dynamics |
Future Price Projection (2023-2030)
- Assumption: Prices remain stable or increase modestly by 2-3% annually, influenced by inflation, manufacturing costs, and market competition.
- Projected AWP in 2030: Between USD 4,650 and USD 4,950 per vial
| Year |
Estimated AWP |
Notes |
| 2023 |
USD 4,400 |
2.3% increase, adjusting for inflation |
| 2025 |
USD 4,650 |
Midpoint projection, moderate market inflation |
| 2030 |
USD 4,950 |
Approximate maximum considering inflation |
Impact of Biosimilars and Competition
Biosimilars for daratumumab are under development, with potential to enter markets by 2028-2030. Introduction of biosimilars typically reduces prices by 20-30%, influencing the price trajectory downward post-2025.
Market Drivers and Constraints
Drivers
- Expansion into earlier lines of therapy.
- Increasing prevalence of multiple myeloma, especially in aging populations.
- Combination therapies improve efficacy, boosting demand.
- Ongoing clinical trials for new indications.
Constraints
- Price sensitivity among payers and patients.
- Potential biosimilar competition.
- Reimbursement policies and formularies.
Summary
Daratumumab (NDC 72205-0224) maintains a dominant position in multiple myeloma treatment, with stable pricing at around USD 4,300 per vial as of 2022. Projections suggest modest price increases through 2030, reaching approximately USD 4,950 per vial, barring biosimilar entry and market shifts. Market expansion, new indications, and combination protocols will support sustained demand.
Key Takeaways
- Daratumumab is a leading antibody therapy for multiple myeloma, with a significant market share.
- Prices have remained stable since 2018, with slight annual increases projected.
- Biosimilars could reduce prices by up to 30% post-2028.
- Market growth driven by expanding indications and combination therapies.
- Pricing strategies will need to adapt to competitive pressures and reimbursement policies.
FAQs
1. What differentiates daratumumab from other multiple myeloma treatments?
It is a first-in-class anti-CD38 monoclonal antibody with proven efficacy across multiple treatment lines, including combination regimens.
2. How might biosimilar entry affect the price of daratumumab?
Biosimilars are expected to reduce list prices by 20-30% once approved and adopted, likely after 2028.
3. Are there new or upcoming indications that could impact demand?
Yes, ongoing clinical trials explore daratumumab in other hematologic malignancies, potentially broadening its use.
4. How do payer policies influence daratumumab pricing?
Reimbursement policies, formulary placement, and negotiated discounts impact effective price and utilization rates.
5. What competitive threats exist for daratumumab?
Biosimilars, emerging therapies, and new combination protocols could challenge its market share.
References
- Grand View Research. (2022). Multiple myeloma therapeutics market size, share & trends analysis.
- Johnson & Johnson. (2022). Darzalex (daratumumab) prescribing information.
- IQVIA. (2022). Market intelligence report on hematology-oncology drugs.
- FDA. (2015). Daratumumab approval announcement.
- EvaluatePharma. (2023). World Oncology Drug Market Outlook.
